Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 0 / 788.069K |
Day Range | - - - |
52 Wk Range | 45.500 - 76.110 |
Market Cap | $6.749B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 56 |
Short Interest | 4.62% |
Days to Cover | 4.76 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Intra-Cellular Therapies (NASDAQ: ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).
The latest price target for Intra-Cellular Therapies (NASDAQ: ITCI) was reported by Cantor Fitzgerald on Friday, February 23, 2024. The analyst firm set a price target for 101.00 expecting ITCI to rise to within 12 months (a possible 44.87% upside). 36 analyst firms have reported ratings in the last year.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $69.72 last updated March 27, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q1 earnings are confirmed for Thursday, May 2, 2024.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.